Review Article

Cartilage Defect Treatments: With or without Cells? Mesenchymal Stem Cells or Chondrocytes? Traditional or Matrix-Assisted? A Systematic Review and Meta-Analyses

Zhantao Deng, Jiewen Jin, Jianning Zhao, and Haidong Xu

Department of Orthopedics, Jinling Hospital, Nanjing University, School of Medicine, 305 Zhongshan East Road, Nanjing, Jiangsu 210002, China

Correspondence should be addressed to Jianning Zhao; zhaojianning.0207@163.com and Haidong Xu; drhaidongxu@163.com

Received 17 July 2015; Revised 1 October 2015; Accepted 8 October 2015

Academic Editor: Fang Yang

Copyright © 2016 Zhantao Deng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Articular cartilage defects have been addressed by using multiple strategies. In the last two decades, promising new strategies by using assorted scaffolds and cell sources to induce tissue regeneration have emerged, such as autologous chondrocyte implantation (ACI) and mesenchymal stem cell implantation (MSCI). However, it is still controversial in the clinical strategies when to choose these treatments. Thus, we conducted a systematic review and meta-analyses to compare the efficacy and safety of different cartilage treatments. In our study, 17 studies were selected to compare different treatments for cartilage defects. The results of meta-analyses indicated that cell-based cartilage treatments showed significant better efficacy than cell-free treatments did (OR: 4.27, 95% CI: 2.19–8.34; WMD: 10.11, 95% CI: 2.69–16.53). Another result indicated that MACT had significant better efficacy than traditional ACI did (OR: 0.49, 95% CI: 0.30–0.82). Besides, the incidence of graft hypertrophy of MACT was slightly lower than that of traditional ACI (OR: 2.43, 95% CI: 1.00–5.94). Current data showed that the cell-based treatments and MACT are better options for cartilage treatments, but more well-designed comparative studies are still needed to enhance our understanding of different treatments for cartilage defects.

1. Introduction

Articular cartilage lines the surface of diarthrodial joints, distributes forces to underlying subchondral bone, and provides a low-friction interface for motion. Articular cartilage defects are common intractable clinical problems because they cannot heal spontaneously. It has been confirmed that cartilage defects often progress to higher grade and larger lesions without proper treatments. They can also lead to the development of osteoarthritis over time [1, 2]. Articular cartilage defects have been addressed by using Pridie drilling, microfracture, mosaicplasty, and abrasion chondroplasty. Pridie drilling involves surgical access to bone marrow space, which promotes blood clot formation, a crude scaffold for fibrocartilaginous repair tissue produced by extravasated bone marrow stem cells. In 1960s, Pridie was the first to advance this concept; subsequent iterations resulted in modern-day microfracture. Another paradigm, mosaicplasty or osteochondral autograft transfer, involves the surgical transfer of mature autologous tissue from a nonloadbearing region to a cartilage defect or transfer of mature allograft tissue from a cadaveric specimen. Arthroplasty is the definitive treatment for end-stage osteoarthritis, but it is only suitable for old patients because of limited durability [3]. However, none of these treatments can generate tissue that adequately recapitulates native cartilage. In the last two decades, promising new strategies by using assorted scaffolds and cell sources to induce chondrocyte regeneration have emerged. As a potential therapeutic option which can regenerate tissues, more and more preclinical and clinical studies were conducted to evaluate the efficacy and safety of scaffold-based cartilage treatments [4].

Biodegradable scaffolds, tissue forming cells, and growth factors are the three principle components of tissue engineering [5, 6]. The rationale for using a scaffold is to have a temporary 3-dimensional structure of biodegradable
Table 1: Short description of major treatments for cartilage defects.

| Technique             | Stage | Scaffold | Procedure                  | Major disadvantages                                                                                                                                 |
|-----------------------|-------|----------|----------------------------|------------------------------------------------------------------------------------------|
| Pridie drilling       | 1 stage | None     | Open procedure             | (a) 2 to 2.5 mm drill holes to access bone marrow; (b) inconsistent results; (c) long recovery; (d) high complication rate. |
| Microfracture         | 1 stage | None     | Arthroscopic procedure     | (a) 0.5 to 1 mm drill holes to access bone marrow; (b) same major disadvantages as Pridie drilling and less impact than Pridie drilling on biomechanics of underlying subchondral. |
| Abrasion chondroplasty| 1 stage | None     | Arthroscopic procedure     | (a) Irreproducible, unreliable; (b) loss of underlying subchondral mechanical support.    |
| Mosaicplasty          | 1 stage | None     | Arthroscopic procedure     | (b) osteochondral plugs 15–20 mm deep; (c) blood clot in interspace.                     |
| Traditional ACI       | 2 stages | None    | Open/arthroscopic procedure | (a) Periosteal patch or collagen membrane; (b) secured by sutures and/or fibrin glue; (c) greatest clinical experience. |
| MACT                  | 1 stage or 2 stages | Hydrogel, fibrous scaffold, decellularized ECM, or composite | Open/arthroscopic procedure | Cells expanded and seeded in scaffold or matrix. |

Because all these treatments have disadvantages and advantages, it is difficult to choose the most appropriate treatment when we are facing cartilage defects (Table 1). Consequently, we conducted this study to review the current comparative clinical trials of scaffold-based cartilage treatments. The aim of our study is to compare the efficacy and safety among cell-based and cell-free cartilage treatments, different cell sources, traditional ACI, and MACT. We hope our study could indicate a new direction for future studies.

2. Methods

2.1. Search Strategy. We conducted a computer-assisted systematic search of PubMed databases from their commencement to July 2015, attempting to find all publications on clinical trials of scaffold-based cartilage defect treatments. Key words and medical subject heading (Mesh) terms for the search of PubMed were as follows: (“cartilage” [Mesh]) AND (“tissuescaffold” [Mesh]) AND “ACI” OR “MACT” OR “mesenchymalstemcell” OR “Microfracture” AND “Clinical trial”. We also reviewed the bibliographies of relevant articles to identify additional studies that might have been missed (Figure 1).

2.2. Selection Criteria. We screened titles and abstracts of identified papers to exclude studies that clearly did not meet the inclusion criteria. Full texts of those selected for further review were retrieved and evaluated. To make sure of the comparability of all the studies, we made some criteria to study selection. The criteria were as follows: (1) They were comparative studies of scaffold-based cartilage treatments;
case series were excluded. (2) The studies must test on human; the in vitro experiments and animal trials were excluded. (3) Reviews, meta-analysis, and meeting reports were excluded. (4) Studies from same authors with same patients were excluded. But two studies conducted by the same author were included in our study because they researched on totally different population. (5) Other criteria were publications being in English; full texts could be found and followed-up for over 1 year.

2.3. Methodological Quality Evaluation. We evaluated the methodological quality of all randomized controlled trials (RCT) by using 7-point modified Jadad scoring system [42]. Meanwhile, observational studies, including case-control studies (CCS) and cohort studies (CS), were evaluated based on the 9-star Newcastle-Ottawa Scale [43]. 4–7 points of Jadad scoring system and 6–9 stars of Newcastle-Ottawa Scale were defined as good quality of the studies.

2.4. Data Extraction. All data were extracted according to the criteria. Discrepancies were discussed and resolved by consensus. Data extracted from each study included the first author, year of publication, types of studies, regions of the population investigated, number of patients of different groups, follow-up, age, gender, locations of lesions, major assessment of efficacy, number of patients who achieved excellent, good, fair, and poor results, and other assessments in the studies. For studies which compared traditional ACI with MACT, graft hypertrophy and frequency of reoperation were extracted to assess the safety. For studies which compared cell-based and cell-free treatments, preoperation and postoperation scores were also extracted. For studies focusing on MSC, brief descriptions were summarized from the studies.

2.5. Meta-Analysis. Stata Statistical Software was used for all the analyses (version 12.0, Stata Corporation, College Station, TX, USA). The measure of estimated effect of interest was OR (odds ratio) or weighted mean difference (WMD) with 95% CI.

We used two models to calculate the pooled relative risk estimates: a fixed-effects model known as the Mantel-Haenszel method [44] and a random-effects model known as the DerSimonian-Laird method [45]. We used the Cochran Q test to evaluate the heterogeneity of the studies [46] and the quantity \( I^2 \) was also calculated [47, 48]. \( I^2 \) is the proportion of total variation contributed by between-study variation, and values of 25%, 50%, and 75% have been regarded as representing low, moderate, and high heterogeneity, respectively. When \( I^2 \) was over 50%, a random-effects model was used to calculate the pooled relative risk estimates. On the contrary, a fixed model was used.

Publication bias was evaluated to find whether the results of the studies were homogeneous. The funnel graph, the Egger regression asymmetry test [49], and the Begg-Mazumdar adjusted rank correlation test [50] were used. When the \( p \) value of Egger's test and Begg's test < 0.05, we considered obvious bias among the studies.

3. Results

3.1. Search Results. We found 2675 records in PubMed database, and 4 records were found from the reference lists. With our selection criteria, we identified 17 studies in our study, including 6 studies which compared ACI with MACT [20, 34–37, 51], 7 studies which compared cell-based with cell-free treatments [27–33], and 4 studies which were focused on MSCI [38–41] (Figure 1). Tables 2, 3, and 4 summarized the characteristics of all the included studies.
Table 2: Characteristics of studies that compared cell-based and cell-free cartilage treatments.

| Study                        | Year | Study design | Regions       | Number of patients | FU | Age Mean, range (yr) | Gender Male/female | Locations | Major assessments of efficacy | Other assessments |
|------------------------------|------|--------------|---------------|-------------------|----|----------------------|-------------------|-----------|-------------------------------|------------------|
| Gudas et al. (athletes) [27] | 2005 | RCT         | Lithuania     | OAT: 28 MF 29     |    | Mean, 37.1 mo.       | 24.3, 15–40       | NR        | Knee                          | ICRS             |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 27          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 15          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 1                |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 14               |                  |
|                              |      |             |               |                   |    |                      |                   |           | 50.67 ± 4.05                  | HSS, MRI         |
|                              |      |             |               |                   |    |                      |                   |           | 85.88 ± 4.69                  |                  |
| Kon et al. [28]              | 2009 | CS          | Italy         | MACT: 40          | 5 yr | 29.0                  | 30.6              | 133/7     | Knee                          | IKDC             |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 29          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 15          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 6               |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 10              |                  |
|                              |      |             |               |                   |    |                      |                   |           | 40.3 ± 15.2                  | Tegner Activity Score |
|                              |      |             |               |                   |    |                      |                   |           | 80.2 ± 19.1                  |                  |
|                              |      |             |               |                   |    |                      |                   |           | 70.2 ± 14.7                  |                  |
| Gudas et al. (children) [29] | 2009 | RCT         | Lithuania     | OAT: 25 MF 22     |    | Mean, 4.2 yr         | 5–15              | NR        | Femoral condyles              | ICRI             |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 16          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 12          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 8               |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 10              |                  |
|                              |      |             |               |                   |    |                      |                   |           | 51 ± 26                       | Tegner Activity Score |
|                              |      |             |               |                   |    |                      |                   |           | 92 ± 9                       |                  |
| Basad et al. [30]            | 2010 | RCT         | Germany       | MACT: 40          | 2 yr | 33.0                  | 37.5              | 25/15     | Knee                          | ICRI             |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 16          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 12          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 8               |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 10              |                  |
|                              |      |             |               |                   |    |                      |                   |           | 55 ± 25                       | Tegner Activity Score |
|                              |      |             |               |                   |    |                      |                   |           | 69 ± 26                       |                  |
| Cole et al. [31]             | 2011 | RCT         | USA           | CAI: 20          | 2 yr | 32.7                  | 33.0              | 14/6      | Knee                          | IKDC             |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 16          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 12          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 8               |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 10              |                  |
|                              |      |             |               |                   |    |                      |                   |           | 44 ± 13                       | SF-36, KOOS      |
|                              |      |             |               |                   |    |                      |                   |           | 52 ± 12                       |                  |
| Kon et al. (soccer players)  | 2011 | CS          | Italy         | MACT: 21          | 2 yr | 23.7, 16–37          | 26.5, 18–35       | 21/0      | Knee                          | IKDC             |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 16          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 12          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 8               |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 10              |                  |
|                              |      |             |               |                   |    |                      |                   |           | 43.2 ± 13.7                  | Tegner Activity Score |
|                              |      |             |               |                   |    |                      |                   |           | 90.5 ± 12.8                  |                  |
|                              |      |             |               |                   |    |                      |                   |           | 86.8 ± 9.7                   |                  |
| Crawford et al. [33]         | 2012 | RCT         | USA           | NeoCart: 21       | 2 yr | 41                    | 39                | 19/2      | Distal femoral cartilage      | IKDC             |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 16          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Excellent + good: 12          |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 8               |                  |
|                              |      |             |               |                   |    |                      |                   |           | Fair + poor: 10              |                  |
|                              |      |             |               |                   |    |                      |                   |           | 44 ± 13                       | SF-36, KOOS      |
|                              |      |             |               |                   |    |                      |                   |           | 52 ± 12                       |                  |

FU: follow-up; RCT: randomized clinical trial; CS: cohort study; MF: microfracture; MACT: matrix-assisted autologous chondrocyte transplantation; ICRS: International Cartilage Repair score; HSS: Hospital for Special Surgery score; IKDC: International Knee Documentation Committee; MRI: magnetic resonance imaging; SF-36: Short-Form-36 Health Survey; TAS: Tegner Activity Score; CAI: cartilage autologous implantation; KOOS: Knee Injury and Osteoarthritis Outcome Score; NeoCart: an autologous cartilage tissue implant; OAT: osteochondral autologous transplantation.
Table 3: Characteristics of studies that compared ACI with MACT.

| Study           | Year | Study design | Regions  | Number of patients | FU    | Age Mean, range (yr) | Gender Male/female | Locations | Major assessments of efficacy | Excellent | Good | Fair | Poor | Graft hypertrophy | Frequency of reoperation | Other assessments     |
|-----------------|------|--------------|----------|--------------------|-------|----------------------|--------------------|-----------|-------------------------------|-----------|------|------|------|------------------|------------------------|-----------------------|
| Bartlett et al. | 2005 | RCT         | England  | ACI-C: 44          | MACT: 47 | 1 yr | 33.2, 15–49 33.4, 17–47 | 54/37              | Knee      | MCS                           | 10        | 15   | 19   | 7    | 6                | 4/44                   | 4/44                  | ICRS, biopsy          |
| Manfredini et al. | 2007 | CCS        | Italy    | ACI-C: 17 Mean,   | MACT: 15 | 15/2 | 32.3, 17–51 35.2, 20–55 | 13/2              | Knee      | HSS                           | 9         | 6    | 2    | 0    | NR               | NR                     | NR                    | ICRS, MRI, and biopsy |
| Ferruzzi et al.  | 2008 | CCS        | Italy    | ACI-P: 48         | MACT: 50 | 5yr  | 32.3 35.2 30/18 36/14 | Knee              | IKDC      | NR                            | 7         | 10   | 23   | 11   | 9                | 4/40                   | 4/10                  | MRI, biopsy           |
| Zefang et al.    | 2010 | RCT        | Germany  | ACI-P: 10         | MACT: 11 | 2yr  | 29.5 29.1 16/5 Femoral condyle | IKDC              | NR        | NR                            | 7         | 10   | 5    | 6    | 2                | 1/10                   | 1/10                  | Lysholm, SF-36, TAS, and MOCART |
| Macmull et al.   | 2012 | CCS        | England  | ACI-C: 25         | MACT: 23 | 2yr  | 34.6, 17–50 35, 21–46 | Patella            | MCS       | 4                | 6         | 6    | 9    | NR   | NR               | NR                     | NR                    | VAS, Bentley score   |
| Panagopoulos et al. | 2012 | CCS       | England  | ACI-P: 11 Mean,   | MACT: 8  | 375 mo. | 32.2, 18–43 71 | Knee              | Lysholm   | 0       | 2    | 4    | 5    | NR   | IKDC, TAS       | 3/11                   | NR                    | Lysholm, SF-36, TAS, and MOCART |

FU: follow-up; RCT: randomized controlled trial; CCS: case-control study; ACI-C: autologous chondrocyte implantation with a flap made of collagen; ACI-P: autologous chondrocyte implantation with periostral flap; MACT: matrix-assisted autologous chondrocyte transplantation; MCS: Modified Cincinnati Rating System; ICRS: International Cartilage Repair Score; HSS: Hospital for Special Surgery score; IKDC: International Knee Documentation Committee; MRI: magnetic resonance imaging; SF-36: Short-Form-36 Health Survey; MOCART: Magnetic Resonance Observation of Cartilage Repair; VAS: Visual Analogue Scale; TAS: Tegner Activity Score.
Table 4: Characteristics of studies that compared MSCI with other cartilage treatments.

| Study                  | Year | Study design | Area     | Number of patients | FU          | Age Mean, range (yr) | Gender Male/female | Locations | Assessments                      | Brief description                                                                 |
|-----------------------|------|--------------|----------|--------------------|-------------|----------------------|--------------------|-----------|----------------------------------|----------------------------------------------------------------------------------|
| Nejadnik et al. [38]  | 2010 | CS USA       | MSCI: 36 ACI: 36 | 2 yr              | 44          | 42.5                 | 18/18              | Knee      | IKDC, ICRS, TAS SF-36, and Lysholm | There was significant improvement in the patients’ quality of life after cartilage repair in both groups. However, there was no difference between the MSCI and the ACI group in terms of clinical outcomes except for Physical Role Functioning, with a greater improvement over time in the MSCI group. |
| Lee et al. [39]       | 2012 | CS Singapore | MSCI: 35 MF: 35 | Mean, 24.5 mo.    | 44          | 44                   | 16/19              | Knee      | ICRS, IKDC, MRI, VAS, and Lysholm | There were no clinically significant adverse events reported through the course of the study. Both groups showed significant improvement in all scores. No significant difference in improvement between the two groups. |
| Yamasaki et al. [40]  | 2014 | CS Japan     | MSCI: 12 Cell-free control: 12 | Mean, 16 mo.    | 63, 49–70   | 15/9                 | Knee      | HSS                              | Both groups showed significant improvement in HSS scores. The difference in clinical improvement between the groups was not significant, the arthroscopic and histological grading score was better in the cell-transplanted group than in the cell-free control group. |
| Gobbi et al. [41]     | 2015 | CS Italy     | MCSE: 18 MACT: 19 | 3 yr              | 45.5        | 43.1                 | 10/8               | Patellae  | IKDC, KOOS, TAS, and VAS         | Both groups showed significant improvement in all scores, but there was no significant difference in improvement between the two groups, except for the IKDC subjective score, which favored the MSCI group. |

FU: follow-up; CS: cohort study; ICRS: International Cartilage Repair score; HSS: Hospital for Special Surgery score; IKDC: International Knee Documentation Committee; SF-36: Short-Form-36 Health Survey; VAS: Visual Analogues scale; TAS: Tegner Activity Score; MF: microfracture; KOOS: Knee injury and Osteoarthritis Outcome Score; MSC: mesenchymal stem cell implantation.
Besides, the number of published studies among the last 15 years increased progressively for both ACI and MACT, MSCs and chondrocytes, and treatments with cells and without cells. Although traditional ACI is still a hot spot for research, the number of studies on MACT has become closer to traditional ACI. On the other hand, MSCs, as a cell source, has the greatest potential, also widely concerned by many researchers. So far, it is still controversial that cartilage treatments with cells is better than treatments without cells; even the number of published studies on treatments with cells is more than treatments without cells, but the publications of both treatments are increasing with similar tendency in recent years (Figure 2(c)).

3.2. Methodological Quality Evaluation Results. For RCTs, only 2 of 7 studies were defined as good quality (4–7 points) because it was difficult to conduct a double-blind trial between two surgical procedures (Table 5). On the other

Figure 2: The number of published studies on cartilage treatments during the last 15 years. (a)–(c) The number of published studies on chondrocytes and MSCs, traditional ACI and MACT, and treatments with or without cells. MSCs: mesenchymal stem cells; ACI: autologous chondrocyte implantation; MACT: matrix-assisted autologous chondrocyte transplantation.
Table 5: Assessment of methodological quality of RCTs by using 7-point modified Jadad scoring system.

| Study                     | Randomization | Allocation concealment | Blinding (observer) | Blinding (patient) | Withdrawals and dropouts | Jadad score |
|---------------------------|---------------|------------------------|---------------------|-------------------|----------------------------|-------------|
| Bartlett et al. [21]      | 2             | 0                      | 0                   | 0                 | 1                          | 3           |
| Zeifan et al. [20]        | 2             | 0                      | 0                   | 0                 | 1                          | 3           |
| Gudas et al. (athletes)   | 1             | 0                      | 0                   | 0                 | 1                          | 2           |
| Gudas et al. (children)   | 1             | 0                      | 0                   | 0                 | 1                          | 2           |
| Basad et al. [30]         | 1             | 0                      | 0                   | 0                 | 1                          | 2           |
| Cole et al. [31]          | 2             | 2                      | 0                   | 0                 | 1                          | 5           |
| Crawford et al. [33]      | 2             | 2                      | 0                   | 0                 | 1                          | 5           |

3.3. Comparison of Efficacy between Cell-Based and Cell-Free Cartilage Treatments. Seven studies were included to compare the efficacy between cell-based and cell-free cartilage treatments. The numbers of patients that achieved excellent and good results, mean scores, and standard deviations were extracted to evaluate the efficacy. Both meta-analyses indicated that cell-based cartilage treatments showed significant better efficacy than cell-free treatments. When meta-analysis was conducted by using the amount of patients who achieved excellent and good results, heterogeneity was considered low. When meta-analysis was conducted by using mean scores and standard deviations, heterogeneity was considered high. No obvious bias was found (Table 7, Figure 3).

3.4. Comparison of Efficacy and Safety between First-Generation ACI and MACT. Six studies were included to compare the efficacy and safety between traditional ACI and MACT. The numbers of patients that achieved excellent and good results were extracted to evaluate the efficacy. As the most common graft-related complication, graft hypertrophy and frequency of reoperation were extracted to evaluate the safety. The results of meta-analyses indicated that MACT showed significant better efficacy than traditional ACI did. Besides, the incidence of graft hypertrophy of MACT was slightly

---

Figure 3: Forest plots and Begg’s funnel plots of studies comparing cell-based with the cell-free cartilage treatments. (a) Forest plots and Begg’s funnel plots conducted by using the number of patients achieved excellent and good results. (b) Forest plots and Begg’s funnel plots conducted by using mean scores and standard deviations.

---

hand, for observational studies, 7 of 10 studies were defined as good quality (6–9 stars) because they were easier to conduct than RCTs (Table 6).
Table 6: Methodological quality of included observational studies based on 9-star Newcastle-Ottawa Scale.

(a)

| CS                  | Representativeness of the exposed cohort | Selection of the nonexposed cohort | Ascertainment of exposure | Outcome of interest was not present at start of study | Control for important factor or additional factor | Assessment of outcome | Follow-up long enough for outcome to occur† | Adequacy of follow-up of cohort | Total score |
|---------------------|-----------------------------------------|-----------------------------------|---------------------------|------------------------------------------------------|------------------------------------------------|------------------------|------------------------------------------|--------------------------------|-------------|
| Kon et al. [28]     | *                                       | *                                 | *                         | *                                                    | *                                              | *                      | *                                        | *                              | 8           |
| Kon et al. (soccer players) [32] | *                                       | *                                 | *                         | *                                                    | *                                              | *                      | *                                        | *                              | 7           |
| Nejadnik et al. [38] | *                                       | *                                 | *                         | *                                                    | *                                              | *                      | *                                        | *                              | 7           |
| Lee et al. [39]     | *                                       | *                                 | *                         | *                                                    | *                                              | *                      | *                                        | *                              | 7           |
| Yamasaki et al. [40] | +                                       | *                                 | *                         | *                                                    | *                                              | *                      | *                                        | *                              | 6           |
| Gobbi et al. [41]   | *                                       | *                                 | *                         | *                                                    | *                                              | *                      | *                                        | *                              | 7           |

(b)

| CCS                 | Adequate definition of cases | Representativeness of cases | Selection of controls | Definition of controls | Control for important factor or additional factor | Ascertainment of exposure | Same method of ascertainment for cases and controls | Nonresponse rate | Total score |
|---------------------|-------------------------------|-----------------------------|-----------------------|------------------------|-------------------------------------------------|--------------------------|-----------------------------------------------------|-----------------|-------------|
| Manfredini et al. [34] | *                             | *                           | *                     | *                      | *                                              | *                        |                                                    |                 | 5           |
| Ferruzzi et al. [35]  | *                             | *                           | *                     | *                      | *                                              | *                        |                                                    |                 | 6           |
| Macmull et al. [36]   | *                             | *                           | *                     | *                      | *                                              | *                        |                                                    |                 | 4           |
| Panagopoulos et al. [37] | *                            | *                           | *                     | *                      | *                                              | *                        |                                                    |                 | 5           |

†Follow-up > 4 years. CS: cohort study; CCS: case-control study.
lower than that of traditional ACI. For frequency of reoperation, no significant difference was found between traditional ACI and MACT. Heterogeneity was considered low when meta-analyses was conducted by using the number of patients who achieved excellent and good results and the incidence of graft hypertrophy. When meta-analysis was conducted by using the frequency of reoperation, heterogeneity was considered moderate. No obvious bias was found (Table 7, Figure 4).

3.5. Comparison between MSCI and Other Treatments. So far, although the researches of MSCs in cartilage repair have already increased year by year, few comparative studies were conducted to evaluate the efficacy and safety of MSCI. In our study, 4 comparative studies focusing on MSCI were included. However, because the data were not enough, no meta-analysis was conducted to evaluate the efficacy and safety of MSCI. But, from the brief descriptions in Table 4, we could easily see that although MSCI showed significant improvement in most of the scoring system, the differences between MSCI groups and control groups were not significant, no matter comparing with MACT, traditional ACI, or cell-free treatments.

4. Discussion

Articular cartilage defects have been addressed by using multiple strategies and the scaffold-based cartilage treatments have become a fascinating treatment option. The traditional ACI, MACT, MSCI, and other scaffold-based cartilage treatments have showed significant improvement in the processes of cartilage repair [24, 52]. The scaffold provides a structural basis for cartilage repair and stimulates the healing processes of damaged tissues. The roles of scaffold have been recognized by most of the researchers or physicians. On the other hand, cells play a controversial role in the scenario. Kon et al. also reviewed the preclinical and clinical studies of scaffold-based cartilage treatments and concluded that scaffold and cells combination were the most investigated option in the preclinical setting, showing generally superior results [4]. This conclusion was similar to our study, but since both strategies remain used clinically, cell-free treatments have the obvious advantages in avoiding cell manipulation and regulatory obstacles with good clinical results. On the other hand, there is still no study which directly compares the outcome of the same scaffold used alone or with cells. These studies usually made comparison with microfracture or other standard cartilage treatments, not with the scaffold alone. Thus, although our study indicated that positive effects of cells were in the healing processes, it is still difficult to clarify the real roles of cells in the healing processes of cartilage defects. More well-designed studies comparing cell-based scaffold with same scaffold alone are needed to clarify the efficiency and safety of cell-based treatments.

Since the first-generation ACI emerged for cartilage treatment, ACI have shown good clinical results for clinical applications. And then, the incorporation of a scaffold or substrate to promote chondrocyte expansion represented the next step in ACI evolution, also known as MACT [3]. MACT also showed good clinical results with multiple advantages, such as better redifferentiation, more homogeneous distribution, better protection, and easier handling for surgical implantation [13–15]. Compared with abrasive technique, the results have been promising. Višňa et al. compared MACT with abrasive technique in a trial of 50 patients and then, at the 1-year follow-up, the MACT group had significantly better outcomes [53]. Basad et al. compared MACT with microfracture in a trial with 60 patients; similar to the comparison with abrasive technique, the MACT group had significant improvement in cartilage repair clinical indices [30]. On the other hand, some researchers made comparisons between traditional ACI and MACT. Although our study indicated that MACT had significant improvement in clinical results compared to traditional ACI with the similar degree of safety, some studies indicated that traditional ACI and MACT were clinically equivalent. Zeifang et al. compared MACT with periosteal flap technique ACI in a trial of 21 patients. The results were equivocal at the 2-year follow-up.

| Table 7: Results of meta-analyses in our study. |
|-----------------------------------------------|
| Number of studies | Assessment | Number of studies | Model, pooled relative risk estimates (95% CI) | Heterogeneity | Publication bias |
|-------------------|------------|-------------------|-----------------------------------------------|---------------|----------------|
| Cell-based versus cell-free | 7 | Excellent and good results | 5 | Fixed, OR, 4.27 (2.19–8.34) | 5.17 | 22.7 0.27 0.221 0.269 |
| | | Mean score and standard deviation | 6 | Random, WMD, 10.11 (2.69–16.53) | 22.93 78.2 0 1 0.953 |
| Traditional ACI versus MACT | 6 | Excellent and good results | 5 | Fixed, OR, 0.49 (0.30–0.82) | 1.50 0 0.83 0.086 0.088 |
| | | Graft hypertrophy | 4 | Fixed, OR, 2.43 (1.00–5.94) | 3.94 23.8 0.27 0.734 0.241 |
| | | Frequency of reoperation | 3 | Fixed, OR, 1.34 (0.53–3.37) | 2.78 28.1 0.25 1 0.593 |

OR: odd ratio; CI: confidence interval; WMD: weighted mean difference; ACI: autologous chondrocyte implantation; MACT: matrix-assisted autologous chondrocyte transplantation.
Bartlett et al. conducted a trial of 91 patients to compare MACT with collagen patch technique ACI. Then, at the 1-year follow-up, two groups reached the similar conclusion, which means that the two groups were clinically equivalent with similar histologic grades by biopsy and hypertrophy rates [51]. We believe that all these differences were caused by patient selection and prejudgments of cartilage defect as well as operations. Besides, in the studies which compared MACT with traditional ACI, only one study had a five-year follow-up. Few studies focused on the long-term efficacy and safety of these two techniques. Maybe the efficiency and safety of traditional ACI and MACT would be much clearer with the help of a long-term of follow-up. That is also one of the reasons why the ACI is still a hot spot in the current researches [24].

With the development of tissue engineering, cell sources have become another hot issue as one of the principle components of tissue engineering. The analysis of the cell sources proposed for the cell-based scaffold treatments indicated that, in preclinical research, MSCs have become the favorite cell type with an increase of studies year by year [24, 54]. However, chondrocyte was still the most common cell type used for cartilage repair in clinical studies (Figure 2). With the self-renewal characteristics, maintenance of “stemness” and potential for differentiation into cells forming multiple mesodermal tissues, MSCs have become an appealing tool for cartilage regeneration treatments. Despite the fact that the MSCs showed an exciting effect on cartilage regeneration in vitro, disappointingly, MSCs did not show great improvement in clinical trials when compared with ACI or...
microfracture [38–41]. But it is still too early to give up on MSCs. As a cell source with so much potential, it is much more difficult to manipulate and regulate than chondrocytes. We believed that with an appropriate way of stimulation and regulation for MSCs, it could greatly improve the efficiency of cartilage treatments. There are some limitations in our study. Firstly, some factors that might affect the clinical results of different treatments were not discussed in our study, such as number of lesions and lesion size. Secondly, only one database was searched and only publications in English were included. Thirdly, in different studies, clinical results were evaluated by different scoring systems and the complications were recorded with different methods, which made the clinical results much more heterogeneous. Fourth, the studies included had different follow-ups and all the clinical results were extracted at the end of follow-ups. As a result, it was difficult to evaluate short-term, mid-term, and long-term efficacy and safety. Fifth, the number of comparative studies of MSC was too small, and the exact data could not be extracted from the publications. Instead, brief descriptions were summarized from the studies. Although there were so many limitations, we believe that the general understanding of cell-based and cell-free treatments, traditional ACI, and MACT could be achieved from our study.

Till now, although we are far from understanding which could be the best strategy for cartilage treatments, an increasing number of studies on this field showed huge research efforts. Cell source and scaffold properties are two of the most popular directions. More well-designed comparative studies are required to enhance our understanding of different cartilage treatments.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgments**

This work was supported by Clinical Science and Technology Project Foundation of Jiangsu Province (BL2012002) and Scientific Research Project of Nanjing Province (201402007), China.

**References**

[1] R. Stahl, S. K. Jain, J. Lutz et al., “Osteoarthritis of the knee at 3.0 T: comparison of a quantitative and a semi-quantitative score for the assessment of the extent of cartilage lesion and bone marrow edema pattern in a 24-month longitudinal study,” *Skeletal Radiology*, vol. 40, no. 10, pp. 1315–1327, 2011.

[2] A. Heijink, A. H. Gomoll, H. Madry et al., “Biomechanical considerations in the pathogenesis of osteoarthritis of the knee,” *Knee Surgery, Sports Traumatology, Arthroscopy*, vol. 20, no. 3, pp. 423–435, 2012.

[3] A. K. Dewan, M. A. Gibson, J. H. Elisseeff, and M. E. Trice, “Evolution of autologous chondrocyte repair and comparison to other cartilage repair techniques,” *BioMed Research International*, vol. 2014, Article ID 272481, 11 pages, 2014.

[4] E. Kon, A. Roffi, G. Filardo, G. Tesei, and M. Marcacci, “Scaffold-based cartilage treatments: with or without cells? A systematic review of preclinical and clinical evidence,” *Arthroscopy: The Journal of Arthroscopic & Related Surgery*, vol. 31, no. 4, pp. 767–775, 2015.

[5] U. A. Stock and J. P. Vacanti, “Tissue engineering: current state and prospects,” *Annual Review of Medicine*, vol. 52, pp. 443–451, 2001.

[6] R. Langer and J. P. Vacanti, “Tissue engineering,” *Science*, vol. 260, no. 510, pp. 920–926, 1993.

[7] B. Grigolo, G. Lisignoli, A. Piacentini et al., “Evidence for redifferentiation of human chondrocytes grown on a hyaluronan-based biomaterial (HYAFF I/II): molecular, immunohistochemical and ultrastructural analysis,” *Biomaterials*, vol. 23, no. 4, pp. 1187–1195, 2002.

[8] F. Vannini, G. Filardo, E. Kon, A. Roffi, M. Marcacci, and S. Giannini, “Scaffolds for cartilage repair of the ankle joint: the impact on surgical practice,” *Foot and Ankle Surgery*, vol. 19, no. 1, pp. 1–8, 2013.

[9] A. R. Amini, C. T. Laurencin, and S. P. Nukavarapu, “Bone tissue engineering: recent advances and challenges,” *Critical Reviews in Biomedical Engineering*, vol. 40, no. 5, pp. 363–408, 2012.

[10] L. Dančík, I. Varga, R. Zamborský, and D. Böhmer, “The tissue engineering of articular cartilage: cells, scaffolds and stimulating factors,” *Experimental Biology and Medicine*, vol. 237, no. 1, pp. 10–17, 2012.

[11] S. P. Nukavarapu and A. R. Amini, “Optimal scaffold design and effective progenitor cell identification for the regeneration of vascularized bone,” in *Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC ’11)*, pp. 2464–2467, IEEE, Boston, Mass, USA, August-September 2011.

[12] S. P. Nukavarapu and D. L. Dorcems, “Osteochondral tissue engineering: current strategies and challenges,” *Biotechnology Advances*, vol. 31, no. 5, pp. 706–721, 2013.

[13] S. Claus, E. Aubert-Foucher, M. Demoor et al., “Chronic exposure of bone morphogenetic protein-2 favors chondrogenic expression in human articular chondrocytes amplified in monolayer cultures,” *Journal of Cellular Biochemistry*, vol. 111, no. 6, pp. 1642–1651, 2010.

[14] K. Gelse, P. Klinger, M. Koch et al., “Thrombospondin-1 prevents excessive ossification in cartilage repair tissue induced by osteogenic protein-1,” *Tissue Engineering Part A*, vol. 17, no. 15-16, pp. 2101–2112, 2011.

[15] T. Nagai, M. Sato, T. Kutsuna et al., “Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair,” *Arthritis Research & Therapy*, vol. 12, no. 5, article R178, 2010.

[16] P. Angele, R. Kujat, M. Nerlich, J. Yoo, V. Goldberg, and B. Johnstone, “Engineering of osteochondral tissue with bone marrow mesenchymal progenitor cells in a derivatized hyaluronan-gelatin composite sponge,” *Tissue Engineering*, vol. 5, no. 6, pp. 545–553, 1999.

[17] G.-I. Im and J. H. Lee, “Repair of osteochondral defects with adipose stem cells and a dual growth factor-releasing scaffold in rabbits,” *Journal of Biomedical Materials Research B: Applied Biomaterials*, vol. 92, no. 2, pp. 552–560, 2010.
[18] X. Q. Wang, E. Wenk, X. H. Zhang, L. Meinel, G. Vunjak-Novakovic, and D. L. Kaplan, "Growth factor gradients via microsphere delivery in bioprosthetic scaffolds for osteochondral tissue engineering," Journal of Controlled Release, vol. 134, no. 2, pp. 81–90, 2009.

[19] D. H. Sohn, L. M. Lottman, L. Y. Lum et al., “Effect of gravity on localization of chondrocytes implanted in cartilage defects,” Clinical Orthopaedics and Related Research, no. 394, pp. 254–262, 2002.

[20] F. Zeifang, D. Oberle, C. Nierhoff, W. Richter, B. Moradi, and R. Gudas, R. Simonaityte, E. Čekanauskas, and R. Tamošiunas, G. Filardo, E. Kon, A. Roffi, A. Di Martino, and M. Marcacci, R. Gudas, R. J. Kalesinskas, V. Kimtys et al., "A prospective, randomized clinical study of osteochondral defects in the knee: periosteum-cover versus matrix-associated autologous chondrocyte implantation: a randomized clinical trial," American Journal of Sports Medicine, vol. 38, no. 5, pp. 924–933, 2010.

[21] W. Bartlett, C. R. Gooding, R. W. J. Carrington, J. A. Skinner, T. W. R. Briggs, and G. Bentley, "Autologous chondrocyte implantation at the knee using a bilayer collagen membrane with bone graft," Journal of Bone and Joint Surgery B, vol. 87, no. 3, pp. 330–332, 2005.

[22] C. R. Gooding, W. Bartlett, G. Bentley, J. A. Skinner, R. Carrington, and A. Flanagan, "A prospective, randomised study comparing two techniques of autologous chondrocyte implantation for osteochondral defects in the knee: periosteum covered versus type I/Ill collagen covered," Knee, vol. 13, no. 3, pp. 203–210, 2006.

[23] J. J. Wood, M. A. Malek, F. J. Frassica et al., "Autologous cultured chondrocytes: adverse events reported to the United States food and drug administration," The Journal of Bone & Joint Surgery—American Volume, vol. 88, no. 3, pp. 503–507, 2006.

[24] G. Filardo, E. Kon, A. Roffi, A. Di Martino, and M. Marcacci, "Scaffold-based repair for cartilage healing: a systematic review and technical note," Arthroscopy: Journal of Arthroscopic and Related Surgery, vol. 29, no. 1, pp. 174–186, 2013.

[25] H. S. Vasilias, B. Danielson, M. Ljunberg et al., "Autologous chondrocyte implantation in cartilage lesions of the knee: long-term evaluation with magnetic resonance imaging and delayed gadolinium-enhanced magnetic resonance imaging technique," American Journal of Sports Medicine, vol. 38, no. 5, pp. 943–949, 2010.

[26] M. J. Stodart, S. Grad, D. Eglin, and M. Alini, "Cells and biomaterials in cartilage tissue engineering," Regenerative Medicine, vol. 4, no. 1, pp. 81–98, 2009.

[27] R. Gudas, R. J. Kalesinskas, V. Kimtys et al., "A prospective randomized clinical study of mosaic osteochondral autologous transplantation versus microfracture for the treatment of osteochondral defects in the knee joint in young athletes," Arthroscopy, vol. 21, no. 9, pp. 1066–1073, 2005.

[28] E. Kon, A. Gobbi, G. Filardo, M. Delcogliano, S. Zaffagnini, and M. Marcacci, "Arthroscopic second-generation autologous chondrocyte implantation compared with microfracture for chondral lesions of the knee: prospective nonrandomized study at 5 years," American Journal of Sports Medicine, vol. 37, no. 1, pp. 33–41, 2009.

[29] R. Gudas, R. Simonaityte, E. Čekanauskas, and R. Tamošiūnas, "A prospective, randomized clinical study of osteochondral autologous transplantation versus microfracture for the treatment of osteochondritis dissecans in the knee joint in children," Journal of Pediatric Orthopaedics, vol. 29, no. 7, pp. 741–748, 2009.

[30] E. Basad, B. Ishaque, G. Bachmann, H. Stürz, and J. Steinmeyer, "Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study," Knee Surgery, Sports Traumatology, Arthroscopy, vol. 18, no. 4, pp. 519–527, 2010.

[31] B. J. Cole, J. Farr, C. S. Winalski et al., "Outcomes after a single-stage procedure for cell-based cartilage repair: a prospective clinical safety trial with 2-year follow-up," The American Journal of Sports Medicine, vol. 39, no. 6, pp. 1170–1179, 2011.

[32] E. Kon, G. Filardo, M. Berruto et al., "Articular cartilage treatment in high-level male soccer players: a prospective comparative study of arthroscopic second-generation autologous chondrocyte implantation versus microfracture," American Journal of Sports Medicine, vol. 39, no. 12, pp. 2549–2557, 2011.

[33] D. C. Crawford, T. M. DeBerardino, and R. J. Williams III, "NeoCart, an autologous cartilage tissue implant, compared with microfracture for treatment of distal femoral cartilage lesions: an FDA phase-II prospective, randomized clinical trial after two years," The Journal of Bone & Joint Surgery—American Volume, vol. 94, no. 11, pp. 979–989, 2012.

[34] M. Manfredini, F. Zerbinati, A. Gildone, and R. Faccini, "Autologous chondrocyte implantation: a comparison between an open periosteal-covered and an arthroscopic matrix-guided technique," Acta Orthopaedica Belgica, vol. 73, no. 2, pp. 207–218, 2007.

[35] A. Ferruzzi, R. Buda, C. Faldini et al., "Autologous chondrocyte implantation in the knee joint: open compared with arthroscopic technique," Journal of Bone and Joint Surgery A, vol. 90, no. 4, pp. 90–101, 2008.

[36] S. Macmull, P. K. Jaiswal, G. Bentley, J. A. Skinner, R. W. I. Carrington, and T. W. R. Briggs, "The role of autologous chondrocyte implantation in the treatment of symptomatic chondromalacia patellae," International Orthopaedics, vol. 36, no. 7, pp. 1371–1377, 2012.

[37] A. Panagopoulos, L. van Niekerk, and I. Triantafillopoulos, "Autologous chondrocyte implantation for knee cartilage injuries: moderate functional outcome and performance in patients with high-impact activities," Orthopedics, vol. 35, no. 1, pp. E6–E14, 2012.

[38] H. Nejadnik, J. H. Hui, E. P. F. Choong, B.-C. Tai, and E. H. Lee, "Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study," The American Journal of Sports Medicine, vol. 38, no. 6, pp. 1110–1116, 2010.

[39] K. B. L. Lee, V. T. Z. Wang, Y. H. Chan, and J. H. P. Hui, "A novel, minimally-invasive technique of cartilage repair in the human knee using arthroscopic microfracture and injections of mesenchymal stem cells and hyaluronic acid—a prospective comparative study on safety and short-term efficacy," Annals of the Academy of Medicine Singapore, vol. 41, no. 11, pp. 511–517, 2012.

[40] S. Yamasaki, H. Mera, M. Itokazu, Y. Hashimoto, and S. Waki-tani, "Cartilage repair with autologous bone marrow mesenchy-mal stem cell transplantation: review of preclinical and clinical studies," Cartilage, vol. 5, no. 4, pp. 196–202, 2014.

[41] A. Gobbi, S. Chaurasia, G. Karmatzikos, and N. Nakamura, "Matrix-induced autologous chondrocyte implantation versus multipotent stem cells for the treatment of large patellofemoral chondral lesions: a nonrandomized prospective trial," Cartilage, vol. 6, no. 2, pp. 82–97, 2015.
[42] A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996.

[43] G. A. Wells, B. Shea, D. O’Connell et al., Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses, Ottawa Hospital Research Institute, Ottawa, Canada, 2012.

[44] N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” Journal of the National Cancer Institute, vol. 22, no. 4, pp. 719–748, 1959.

[45] R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986.

[46] W. G. Cochran, “The combination of estimates from different experiments,” Biometrics, vol. 10, no. 1, pp. 101–129, 1954.

[47] J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002.

[48] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003.

[49] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997.

[50] C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994.

[51] W. Bartlett, J. A. Skinner, C. R. Gooding et al., “Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee. A prospective, randomised study,” The Journal of Bone & Joint Surgery—British Volume, vol. 87, no. 5, pp. 640–645, 2005.

[52] E. Kon, G. Filardo, A. Roffi, L. Andriolo, and M. Maracci, “New trends for knee cartilage regeneration: from cell-free scaffolds to mesenchymal stem cells,” Current Reviews in Musculoskeletal Medicine, vol. 5, no. 3, pp. 236–243, 2012.

[53] P. Višňa, L. Paša, I. Čižmár, R. Hart, and J. Hoch, “Treatment of deep cartilage defects of the knee using autologous chondrograft transplantation and by abrasive techniques—a randomized controlled study,” Acta Chirurgica Belgica, vol. 104, no. 6, pp. 709–714, 2003.

[54] G. Filardo, H. Madry, M. Jelic, A. Roffi, M. Cucchiarini, and E. Kon, “Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 21, no. 8, pp. 1717–1729, 2013.